doi:10.3969/j.issn.1673-8640.2018.10.019

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 8

[1]	赵笔辉. 应用日立7180全自动生化分析仪的检测时序处理交叉污染[J]. 检验医学,2016,31(2):140-143.
[2]	颜霞,程正江,金梅,等. 西门子ADVIA2400全自动生化分析仪检测总胆汁酸中的试剂污染分析及解决方案[J]. 检验医学,2017,32(7):619-622.
[3]	李光富,胡孝彬,陈江,等. 全自动生化分析仪测定高密度脂蛋白胆固醇后对镁检测的交叉污染[J]. 检验医学,2009,24(8):565-567.
[4]	王传发. 日立7600生化分析仪检测血清镁中的试剂交叉污染及其消除措施[J]. 检验医学,2010,25(6):465-467.
[5]	谭晓霞,陈鹏龙,吴新华,等. 自动生化分析仪试剂携带污染干扰镁测定排除方法[J]. 中国卫生检验杂志,2011,21( 2):452-453.
[6]	CAMERON S J,GERHARDT G,ENGELSTAD M,et al.Interference in clinical chemistry assays by the hemoglobin-based oxygen carrier,Hemospan[J]. Clin Biochem,2009,42(3):221-224.
[7]	郑卫波. 生化分析仪总蛋白试剂携带污染干扰镁测定的排除方法[J]. 检验医学,2014,29(6):612.
[8]	LIPPI G,DAVES M,MATTIUZZI C.Interference of medical contrast media on laboratory testing[J]. Biochem Med(Zagreb),2014,24(1):80-88.

组别	东芝TBA120	日立7600
对照	0.88±0.06	0.87±0.05
先测ALT	0.87±0.07	0.87±0.05
先测AST	0.86±0.08	0.87±0.05
先测GGT	0.88±0.07	0.88±0.08
先测TP	4.67±0.23^*#	0.88±0.06
先测Alb	0.88±0.07	0.87±0.05
先测TB	0.45±0.04^*#	0.88±0.06
先测DBil	0.45±0.06^*#	0.87±0.05

组别	东芝TBA120	日立7600
对照	0.88±0.06	0.87±0.05
先测ALT	0.87±0.07	0.87±0.05
先测AST	0.86±0.08	0.87±0.05
先测GGT	0.88±0.07	0.88±0.08
先测TP	4.67±0.23^*#	0.88±0.06
先测Alb	0.88±0.07	0.87±0.05
先测TB	0.45±0.04^*#	0.88±0.06
先测DBil	0.45±0.06^*#	0.87±0.05

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 8

Related Articles 15

Recommended Articles

Metrics